Patent Expiration of Zanidip Will Bring Intense Competition Next Year

The pharmaceutical industry expects an increased level of competition among the domestic makers of first generics next year, as the patent for Zanidip (active ingredient: lercanidipine hydrochloride) will be expired in December.

Currently, there are eleven pharmaceutical firms that have received production approvals for lercanidipine generics based on the qualified bioequivalence testing. T...